These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 21172842)

  • 1. Randomized, double-blind, placebo-controlled trial of hydroxyurea in spinal muscular atrophy.
    Chen TH; Chang JG; Yang YH; Mai HH; Liang WC; Wu YC; Wang HY; Huang YB; Wu SM; Chen YC; Yang SN; Jong YJ
    Neurology; 2010 Dec; 75(24):2190-7. PubMed ID: 21172842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of hydroxyurea in spinal muscular atrophy cells and patients.
    Liang WC; Yuo CY; Chang JG; Chen YC; Chang YF; Wang HY; Ju YH; Chiou SS; Jong YJ
    J Neurol Sci; 2008 May; 268(1-2):87-94. PubMed ID: 18166199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Responsiveness of the motor function measure in patients with spinal muscular atrophy.
    Vuillerot C; Payan C; Iwaz J; Ecochard R; Bérard C;
    Arch Phys Med Rehabil; 2013 Aug; 94(8):1555-61. PubMed ID: 23380348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SMA CARNI-VAL trial part I: double-blind, randomized, placebo-controlled trial of L-carnitine and valproic acid in spinal muscular atrophy.
    Swoboda KJ; Scott CB; Crawford TO; Simard LR; Reyna SP; Krosschell KJ; Acsadi G; Elsheik B; Schroth MK; D'Anjou G; LaSalle B; Prior TW; Sorenson SL; Maczulski JA; Bromberg MB; Chan GM; Kissel JT;
    PLoS One; 2010 Aug; 5(8):e12140. PubMed ID: 20808854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Somatropin treatment of spinal muscular atrophy: a placebo-controlled, double-blind crossover pilot study.
    Kirschner J; Schorling D; Hauschke D; Rensing-Zimmermann C; Wein U; Grieben U; Schottmann G; Schara U; Konrad K; Müller-Felber W; Thiele S; Wilichowski E; Hobbiebrunken E; Stettner GM; Korinthenberg R
    Neuromuscul Disord; 2014 Feb; 24(2):134-42. PubMed ID: 24300782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Valproic Acid for Spinal Muscular Atrophy: A Systematic Review and Meta-Analysis.
    Elshafay A; Hieu TH; Doheim MF; Kassem MAM; ELdoadoa MF; Holloway SK; Abo-Elghar H; Hirayama K; Huy NT
    CNS Drugs; 2019 Mar; 33(3):239-250. PubMed ID: 30796634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized, double-blind, placebo-controlled trial of phenylbutyrate in spinal muscular atrophy.
    Mercuri E; Bertini E; Messina S; Solari A; D'Amico A; Angelozzi C; Battini R; Berardinelli A; Boffi P; Bruno C; Cini C; Colitto F; Kinali M; Minetti C; Mongini T; Morandi L; Neri G; Orcesi S; Pane M; Pelliccioni M; Pini A; Tiziano FD; Villanova M; Vita G; Brahe C
    Neurology; 2007 Jan; 68(1):51-5. PubMed ID: 17082463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of olesoxime in patients with type 2 or non-ambulatory type 3 spinal muscular atrophy: a randomised, double-blind, placebo-controlled phase 2 trial.
    Bertini E; Dessaud E; Mercuri E; Muntoni F; Kirschner J; Reid C; Lusakowska A; Comi GP; Cuisset JM; Abitbol JL; Scherrer B; Ducray PS; Buchbjerg J; Vianna E; van der Pol WL; Vuillerot C; Blaettler T; Fontoura P;
    Lancet Neurol; 2017 Jul; 16(7):513-522. PubMed ID: 28460889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SMA CARNIVAL TRIAL PART II: a prospective, single-armed trial of L-carnitine and valproic acid in ambulatory children with spinal muscular atrophy.
    Kissel JT; Scott CB; Reyna SP; Crawford TO; Simard LR; Krosschell KJ; Acsadi G; Elsheik B; Schroth MK; D'Anjou G; LaSalle B; Prior TW; Sorenson S; Maczulski JA; Bromberg MB; Chan GM; Swoboda KJ;
    PLoS One; 2011; 6(7):e21296. PubMed ID: 21754985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reliability and validity of outcome measures of in-hospital and at-home visits in a randomized, double-blind, placebo-controlled trial for spinal muscular atrophy.
    Chen TH; Yang YH; Mai HH; Liang WC; Wu YC; Wang HY; Jong YJ
    J Child Neurol; 2014 Dec; 29(12):1680-4. PubMed ID: 24163397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hydroxyurea enhances SMN2 gene expression in spinal muscular atrophy cells.
    Grzeschik SM; Ganta M; Prior TW; Heavlin WD; Wang CH
    Ann Neurol; 2005 Aug; 58(2):194-202. PubMed ID: 16049920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protocol for a phase II, monocentre, double-blind, placebo-controlled, cross-over trial to assess efficacy of pyridostigmine in patients with spinal muscular atrophy types 2-4 (SPACE trial).
    Stam M; Wadman RI; Wijngaarde CA; Bartels B; Asselman FL; Otto LAM; Goedee HS; Habets LE; de Groot JF; Schoenmakers MAGC; Cuppen I; van den Berg LH; van der Pol WL
    BMJ Open; 2018 Jul; 8(7):e019932. PubMed ID: 30061431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of hydroxyurea in providing transfusion independence in β-thalassemia.
    Ansari SH; Shamsi TS; Ashraf M; Perveen K; Farzana T; Bohray M; Erum S; Mehboob T
    J Pediatr Hematol Oncol; 2011 Jul; 33(5):339-43. PubMed ID: 21602718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lamotrigine adjunctive therapy among children and adolescents with primary generalized tonic-clonic seizures.
    Trevathan E; Kerls SP; Hammer AE; Vuong A; Messenheimer JA
    Pediatrics; 2006 Aug; 118(2):e371-8. PubMed ID: 16847080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of leuprorelin in patients with spinal and bulbar muscular atrophy (JASMITT study): a multicentre, randomised, double-blind, placebo-controlled trial.
    Katsuno M; Banno H; Suzuki K; Takeuchi Y; Kawashima M; Yabe I; Sasaki H; Aoki M; Morita M; Nakano I; Kanai K; Ito S; Ishikawa K; Mizusawa H; Yamamoto T; Tsuji S; Hasegawa K; Shimohata T; Nishizawa M; Miyajima H; Kanda F; Watanabe Y; Nakashima K; Tsujino A; Yamashita T; Uchino M; Fujimoto Y; Tanaka F; Sobue G;
    Lancet Neurol; 2010 Sep; 9(9):875-84. PubMed ID: 20691641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma.
    Hoyles RK; Ellis RW; Wellsbury J; Lees B; Newlands P; Goh NS; Roberts C; Desai S; Herrick AL; McHugh NJ; Foley NM; Pearson SB; Emery P; Veale DJ; Denton CP; Wells AU; Black CM; du Bois RM
    Arthritis Rheum; 2006 Dec; 54(12):3962-70. PubMed ID: 17133610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase 1 trial of riluzole in spinal muscular atrophy.
    Russman BS; Iannaccone ST; Samaha FJ
    Arch Neurol; 2003 Nov; 60(11):1601-3. PubMed ID: 14623733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathophysiological insights derived by natural history and motor function of spinal muscular atrophy.
    Farrar MA; Vucic S; Johnston HM; du Sart D; Kiernan MC
    J Pediatr; 2013 Jan; 162(1):155-9. PubMed ID: 22809660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal.
    Spuls PI; Hooft L
    Br J Dermatol; 2012 Oct; 167(4):710-3; discussion 714-5. PubMed ID: 23013312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.